Publications
-
FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity
Journal of American Society of Nephrology
-
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
The New England Journal of Medicine
-
The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid
Alimentary Pharmacology & Therapeutics
-
Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis
Drug Discovery Today
Patents
-
Bile Acid Derivatives as FXR Ligands for the Prevention or Treatment of FXR-Mediated Diseases or Conditions
US 8,546,365
-
Bile Acid Derivatives as FXR Ligands for the Prevention or Treatment of FXR-Mediated Diseases or Conditions
US 7,932,244
-
Bile Acid Derivatives as FXR Ligands for the Prevention or Treatment of FXR-Mediated Diseases or Conditions
US 9,763,964
-
Bile Acid Derivatives as FXR Ligands for the Prevention or Treatment of FXR-Mediated Diseases or Conditions
US 7,858,608
-
Bile Acid Derivatives as FXR Ligands for the Prevention or Treatment of FXR-Mediated Diseases or Conditions
US 9,090,651
-
Treatment of Fibrosis Using FXR Ligands
US 9,498,484
-
Treatment of Fibrosis Using FXR Ligands
US 10,258,633
Languages
-
English, French, Italian, German
-
People also viewed
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More